STING1 and neoplasm: In B16 melanoma tumor-bearing mice, an intravenous administration of the STING agonist cGAMP decreased the number of GR1+ and especially Ly6G+ PMN-MDSCs in the spleen and tumor while suppressing the production of ROS and NO from MDSCs and abolishing their suppressive function (118).